80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo
Phase 3Completed 2 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriasis
Conditions
Psoriasis
Trial Timeline
Nov 16, 2011 → Sep 20, 2018
NCT ID
NCT01474512About 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo is a phase 3 stage product being developed by Eli Lilly for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01474512. Target conditions include Psoriasis.
What happened to similar drugs?
20 of 20 similar drugs in Psoriasis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01474512 | Phase 3 | Completed |
Competing Products
20 competing products in Psoriasis